Hematology Frontier

At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the "EHA Research Excellence Award" to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor Vassiliou reviewed the landmark research conducted by his team over the past 15 years regarding the identification of driver genes in acute myeloid leukemia (AML), the evolutionary logic of clonal hematopoiesis (CH), and the development of clinical prediction tools.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Johannes Schetelig from the Technical University Dresden and the German Bone Marrow Donor Center (DKMS) presented a highly anticipated Late-breaking Abstract. This study is a large-scale randomized controlled trial (RCT) designed to compare Anti-T Lymphocyte Globulin (ATLG) and Post-Transplant Cyclophosphamide (PTCy) "head-to-head" for the prophylaxis of Graft-versus-Host Disease (GVHD) in HLA-matched or partially matched unrelated donor hematopoietic cell transplantation (HCT).

At the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Josep Maria Ribera from the Josep Carreras Leukemia Research Institute and the Catalan Institute of Oncology (ICO) was honored with the "EHA Clinical Excellence Award." In his subsequent award lecture, Prof. Ribera systematically reviewed the successful transformation of Acute Lymphoblastic Leukemia (ALL) from a "diagnostic deficiency period" to a "precision immunotherapy period," shared the successful experiences of the Spanish PETEMA group, and outlined a future "chemo-free" treatment blueprint.

At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has become a major challenge for clinicians. This meeting invited Professor Joseph Mikhael from City of Hope, Professor Maria-Victoria Mateos from the University Hospital of Salamanca, and Professor Xavier Leleu from Poitiers University Hospital to conduct an in-depth discussion on "Managing the Burden of MM Treatments."

In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled "From gene profiles to therapy profiles - a quarter century of molecular hematology." Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis of the evolutionary path of hematologic malignancies, represented by Acute Myeloid Leukemia (AML), from morphological classification to molecular precision diagnosis and treatment.

In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment, direct head-to-head data for the second-generation inhibitor gilteritinib versus midostaurin in the context of first-line intensive chemotherapy were previously a blank.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Martin Schrappe, on behalf of the AIEOP-BFM consortium, announced the latest analysis data from the Phase III randomized controlled clinical trial AIEOP-BFM ALL 2017. This study aimed to explore the clinical benefits of using the bispecific antibody Blinatumomab to completely replace two cycles of high-intensity toxic chemotherapy in newly diagnosed pediatric and adolescent patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL). The results showed that this strategy not only significantly improved the event-free survival (EFS) rate of patients but also substantially reduced treatment-related toxicity and transplant-related mortality.

Although progress has been made in the treatment of Acute Myeloid Leukemia (AML) over the past few decades, clinical options remain very limited for patients with relapsed/refractory (R/R) disease. Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary breakthroughs in B-cell malignancies; however, its application in the field of AML has faced significant challenges due to limitations in target selection, patient T-cell quality, and potential toxicities (such as long-term bone marrow suppression).

In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing a transformation from traditional chemo-immunotherapy to precision targeted therapies centered on BTK inhibitors (BTKi).

At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab (VR regimen) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).